fbpx

SuperBetter Partners With Psych Hub To Provide Videos About Mental Health

People around the world play SuperBetter to be stronger and more successful at achieving goals and overcoming challenges across many areas of their lives, including their mental health.

Today, we have great news to share — especially for those playing SuperBetter to tackle depression, anxiety and other challenges related to mental health. Psych Hub has partnered with SuperBetter to provide access to a library of high quality educational videos featuring mental health topics. These videos are available at no cost to the SuperBetter Community.

Psych Hub is a mission-aligned organization that has created a library of short, educational videos on various topics related to mental health such as depression, anxiety, bipolar, PTSD, eating disorders, and evidence based treatments. It was founded by Marjorie Morrison, former CEO of PsychArmor Institute, (a non-profit organization dedicated to providing free online courses about an array of issues of interest to the military community and their families), and Patrick J. Kennedy, former congressman of Rhode Island, mental health advocate, and founder of The Kennedy Forum.

Psych Hub’s mission is to spread greater knowledge and awareness about mental health issues and to decrease the stigma associated with them. By combining clinical research with the art of storytelling, Psych Hub videos provide mental health education that is accessible to everyone.

Psych Hub is partnering with respected organizations like SuperBetter as part of its commitment to bringing accurate and reliable information about mental health to a broader audience. As a partner we have our own page on Psych Hub for the SuperBetter Community. On this page are many videos that we think SuperBetter fans and users may find of interest. We invite you to click over, check them out, and share them with your family, friends, colleagues, and communities!

Lyfebulb and UnitedHealth Group Announce The Winner of Their 2019 Innovation Challenge for Patient Entrepreneurs

Challenge brought together 10 finalists who are building solutions for those affected by depression and anxiety

MINNETONKA, Minn., and NEW YORK (July 24, 2019) Lyfebulb LLC and UnitedHealth Group (NYSE: UNH) are pleased to announce that Rohan Dixit of Lief Therapeutics was selected as the winner of the “Addressing Unmet Needs in Depression & Anxiety: An Innovation Challenge.” Lief Therapeutics has developed an intuitive, data-driven wearable consumer product for anxiety used to teach the skill of mindfulness using heart rate variability.

Rohan was selected from a group of passionate innovators who were finalists in the Challenge, including Jay Brown of Health Behavior Solutions; Matt Loper of Wellth; Lisa McLaughlin of Workit Health; Katherine Ponte of ForLikeMinds; Jan Samzelius of NeuraMetrix; Dr. Ryan Stoll of COMPASS for Courage; Dr. Mehran Talebinejad of NeuroQore; Quayce Thomas of Timsle; and Keith Wakeman of SuperBetter.

Dennis Urbaniak, Chief Digital Officer of Havas Health & You, who served as Chair of the Jury commented, “Rohan not only has a mission and purpose that aligned with the criteria of the challenge, but also has taken a conventional approach and reimagined it through the patient experience with evidence-based science behind it. Additionally, he has identified viable pathways to commercialization.”

The Innovation Challenge was open to established companies of all sizes that are founded or led by an entrepreneur who has been affected by depression and anxiety, whether as a patient or through a loved one, and who has created a product or service to address an unmet need identified through personal experience. The 10 finalists gathered at UnitedHealth Group’s headquarters for two days of meetings, workshops and pitch presentations. The event culminated with a panel of esteemed judges selecting Rohan Dixit for the $25,000 award.

“Partnering with UnitedHealth Group for a second year in a new therapeutic area which impacts all of healthcare is tremendous for Lyfebulb,” said Dr. Karin Hehenberger, Founder and CEO of Lyfebulb. “We have established a community of people affected by and caring about depression and anxiety, from which we sourced ten exceptional patient entrepreneurs to join us in Minnetonka over the past few days. Their passion and determination to solve daily issues that burden so many individuals came through clearly during the pitches.”

The judges included experts from the patient, business and medical communities including Mike Christy, Senior Vice President of Venture Development at UnitedHealth Group; Dr. Raja M. David, Founder and Owner of Minnesota Center for Collaborative/Therapeutic Assessment; Matt Kudish, Executive Director at NAMI-NYC (National Association of Mental Illness); AnnMarie Otis, Patient Advocate; Dr. Bethany Ranes, Research Associate at UnitedHealth Group; and Dennis Urbaniak, Chief Digital Officer at Havas Health & You.

“Through this innovation challenge, we learned from patients and caretakers who live and breathe the challenges of this disease every day,” said Dr. Deneen Vojta, Executive Vice President and Chief Medical Officer of Research & Development at UnitedHealth Group.  “We see depression and anxiety touch all populations we serve and we valued the opportunity to bring together entrepreneurs, health care providers, patient advocates and business leaders at the summit. Together, we can help bring the most innovative, effective tools – inspired by personal experiences – into the marketplace.”

Lyfebulb and UnitedHealth Group Announce Finalists for 2019 “Addressing Unmet Needs in Depression and Anxiety: An Innovation Challenge”

Dear Lyfebulb Community,

EXCITING NEWS: We have chosen the 10 finalists for our Innovation Challenge with UnitedHealth Group in Depression and Anxiety! Listed below, each of our Patient Entrepreneurs were selected because of their personal connection to Depression and/or Anxiety that inspired them to innovate in the mental health space to satisfy an unmet need in the patient community.

  • Health Behavior Solutions, Jay Brown – Digital therapeutics company with apps aimed at improving health outcomes for individuals with mental health conditions
  • Lief Therapeutics, Rohan Dixit – Smart patch that tracks and improves biomarkers of mental health
  • Wellth, Matt Loper – Digital health company using behavioral economics to help motivate individuals to better manage their chronic conditions by building lasting, healthy habits
  • Workit Health, Lisa McLaughlin – Telehealth addiction care company that provides medication assisted treatment and counseling by phone or web
  • ForLikeMinds, Katherine Ponte – Online peer support community for people living with or supporting someone with mental illness, substance use, or stressful life events
  • NeuraMetrix, Inc., Jan Samzelius – Non-invasive software technology that measures the inconsistency of Typing Cadence to aid in monitoring cognitive and motor functions of patients with CNS diseases and psychiatric disorders
  • COMPASS for Courage, Dr. Ryan Stoll – Program using the best available evidence-based tools to support anxious youth to become more resilient, confident, and courageous
  • NeuroQore, Dr. Mehran Talebinejad – Rapid 4-day treatment for major depressive disorder patients at imminent risk of suicide
  • Timsle Inc, Quayce Thomas – Social accountability network designed to help people improve their health, with the support of friends and family
  • SuperBetter, Keith Wakeman – Digital mental health and resilience app to improve the ability to stay strong, motivated and optimistic in the face of difficult obstacles

On our panel of judges, we are also excited to have:

  • Mike Christy: Senior Vice President of Ventures for UnitedHealth Group Research & Development;
  • Raja M. David, PsyD, ABPP, LP: Founder & Owner of the Minnesota Center for Collaborative/Therapeutic Assessment;
  • Matt Kudish: Executive Director of the National Alliance on Mental Illness of New York City (NAMI-NYC);
  • AnnMarie Otis: Patient Advocate and Lyfebulb Ambassador;
  • Bethany Ranes, PhD.: Senior research scientist from UnitedHealth Group Research and Development who specializes in cognitive neuroscience and mental health; and
  • Dennis Urbaniak: Chief Digital Officer of Havas Health & You and CEO of Havas Health Plus.

Click here to learn more about the 10 finalists as well as an overview of the Challenge.

Celgene, Lyfebulb put patient spin on MS innovation challenge

Innovation challenges continue to proliferate in the pharma industry, and Celgene’s is the latest, seeking crowdsourced solutions for multiple sclerosis (MS) patients. Its partnership with Lyfebulb is unique, however, in that it only accepted entries from patients or direct relations of patients.

In the MS challenge with Celgene, Lyfebulb and its Big Biotech partner have narrowed the field to 10 patient entrepreneur finalists, with a “Shark Tank”-style finish set for June 12-13. Each finalist will get 10 minutes to present to a professional panel of judges that will include a patient advocacy group lead, patient ambassador and venture capitalist, plus reps from pharma and the insurance industry. At the end of the second day, one winner will be chosen for the top prize of $25,000. But even more valuable than the money, said Lyfebulb founder and CEO Karin Hehenberger, is the exposure to pharma executives, additional funding sources and other influential industry players.

Celgene first approached Lyfebulb last year in an effort to better understand MS patient needs as it readied its first multiple sclerosis treatment for market. Since then, the FDA has pushed back on Celgene’s candidate ozanimod with a refuse-to-file notice and a request more data on preclinical and clinical pharmacology, delaying the company’s NDA filing until March of this year. The new ozanimod data hit its targets, though, and analysts project the drug could still reach $2 billion in sales in the already competitive oral MS drug market. In the meantime, Celgene has also become an M&A partner for Bristol-Myers Squibb in a $74 billion deal approved by shareholders in April.

The Celgene challenge for multiple sclerosis is Lyfebulb’s seventh patient-sourced contest, with previous partners including Novo Nordisk for diabetes, Helsinn Healthcare for oncology and United Healthcare for depression and anxiety solutions.

Hehenberger, a physician and Type 1 diabetes patient who has walked the walk of chronic disease with two transplants and a pacemaker implant, launched the company in 2014 to help give patients a voice in industry solutions.

“We believe insights and solutions from patients can be leveraged by pharma and by tech and device companies to enhance their pipelines, to get closer to patients and to learn what it’s like to live with these diseases,” she said. “For the patients, they finally really get heard. For pharma companies, instead of just being patient-centric, they now work side by side with patients.”

Tuesday, May 21, 2019

Source: Beth Snyder Bulik, FiercePharma

Lyfebulb and UnitedHealth Group Launch Second Annual Innovation Challenge for Patient Entrepreneurs

Lyfebulb and UnitedHealth Group Launch Second Annual Innovation Challenge for Patient Entrepreneurs

  • Challenge aims to inspire patient-driven innovation in the management of depression and anxiety
  • Finalists will compete at UnitedHealth Group headquarters for a chance to win $25,000

group image for UnitedHealth Innovation Challenge

MINNETONKA, Minn. and NEW YORK, May 13, 2019 /PRNewswire/ Lyfebulb LLC and UnitedHealth Group (NYSE: UNH) invite patient entrepreneurs to compete in “Empowering Patients: An Innovation Challenge,” for the second annual Lyfebulb and UnitedHealth Group Innovation Award.

This year’s challenge will recognize the top patient entrepreneurs developing innovative ideas for better management of depression and anxiety using health care information technology, medical devices, diagnostics, consumer products or services.

UnitedHealth Grouup logo

Eligible companies are those that are founded or led by a patient entrepreneur: someone who has been personally affected by depression or anxiety (themselves or through a loved one) and who develops a product or service to address an unmet need identified through personal experience. Companies based in the United States or Canada (excluding Quebec) are eligible to apply. The application, detailed rules and eligibility criteria can be found at click here. Applications are open until 11:59pm EST on May 31, 2019.

“Depression and anxiety are issues that particularly affect people living with chronic disease,” said Dr. Karin Hehenberger, founder and CEO of Lyfebulb. “We are honored to work with UnitedHealth Group on an issue that affects so many people in our community and nationwide. We are eager to tap into the unique insights that patients have, and leverage those to identify user-driven solutions by patient entrepreneurs for issues they face.”

A joint steering committee composed of Lyfebulb and UnitedHealth Group executives will conduct a thorough sourcing and screening process, and select 10 finalists who will be invited to the Empowering Patients event July 23-24, 2019, at UnitedHealth Group’s headquarters in Minnetonka. There, the finalists will pitch their solutions to a panel of experts (a jury) from the business, medical and patient communities. The jury will award a $25,000 prize to the company with the most innovative and impactful solution at the closing ceremony.

“Depression and anxiety weave through all areas of disease – chronic and acute – yet they are understudied and underserved in terms of dialogue and solutions today in the United States,” said Gene Baker, Ph.D., a research fellow at UnitedHealth Group. “We are grateful for the opportunity to partner with Lyfebulb and look forward to hearing from patients and entrepreneurs to learn more about the innovative, patient-driven solutions to help people living with depression and chronic disease.”

About Lyfebulb
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry (manufacturers and payers) to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis and depression/anxiety.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a diversified health care company dedicated to helping people live healthier lives and helping to make the health system work better for everyone. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at unitedhealthgroup.com or follow @UnitedHealthGrp on Twitter.

Contact:

Lyfebulb
Karin Hehenberger, M.D., Ph.D., CEO
917-575-0210; Karin@lyfebulb.com

UnitedHealth Group
Tyler Mason
424-333-6122, tyler.mason@uhg.com

Lyfebulb and Celgene Announce Finalists for 2019 “Addressing Unmet Needs in MS: An Innovation Challenge”

Lyfebulb and Celgene Announce Finalists for 2019 “Addressing Unmet Needs in MS: An Innovation Challenge”

Finalist patient entrepreneurs recognized for potential of innovations in multiple sclerosis (MS)

Image at Celegene 2019 challenge

NEW YORK, May 10, 2019 /PRNewswire/ Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced the 10 finalists chosen for the Lyfebulb-Celgene 2019 “Addressing Unmet Needs in MS: An Innovation Challenge.”

The following finalists will compete at the Innovation Challenge Summit on June 13, 2019, for a $25,000 monetary grant to further develop their proposed innovations:

Celgene Logo with tagline

  • Abilitech Medical, Shawna Persaud: Medical device intended to help people with MS with mobility challenges use their arms
  • AXS Map, Jason DaSilva: Web platform that allows users to locate, rate and review the accessibility of any location in the world
  • BeCareLink, Alan Gilbert: Predictive artificial intelligence (AI) digital therapeutics platform which remotely measures clinically validated assessments of cognition and motion to help improve quality of care and reduce costs for people with MS
  • C. Light Technologies, Inc, Zachary Helft: Neurotech and AI technology using eye motion measured on the cellular scale to monitor disease state in people with MS for treatment efficacy feedback
  • Dance4Healing, Amy Li: AI-powered telehealth live video platform which brings community, exercise and physical rehabilitation into the home to encourage healthy behavior change
  • Icometrix, Wim Van Hecke: AI-based brain imaging solutions to monitor disease progression
  • Leoplus USA, Kinza Kasher: Device and app which aims to support communications between patients and care partners
  • Loro co., David Hojah: Socially assistive companion robot for people with mobility challenges
  • Moodify, Kate Milliken: Web-based tool which builds communities, aims to reduce loneliness, creates searchable content moments and tracks the emotional journey
  • ThermApparel LLC, Bradley Dunn: Lightweight, comfortable and concealable cooling apparel for people with extreme heat sensitivity

“At Lyfebulb, we build communities of patients with chronic disease around a message of inspiration and hope for the future. Each of these patient entrepreneurs is inspirational, as they have taken their frustrations of living with their disease – or observing it in a loved one – and are working to turn those insights into business solutions to help members of the MS community live their daily lives more comfortably,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb.

These finalists are being recognized as outstanding patient entrepreneurs – those who have been affected by MS as either a patient, loved one or support partner – whose companies are helping develop solutions to address an unmet need in MS. A “pitch session” will be held at the Challenge Summit, and a winner will be chosen by a diverse group of experts in the MS, healthcare and business communities. The panel of judges will include:

  • Tim Coetzee, PhD: Chief Advocacy, Services and Research Officer, National Multiple Sclerosis Society;
  • Adam Fine: General Partner and CEO, Windham Venture Partners;
  • Elizabeth Jones: MS Patient Ambassador;
  • Darin T. Okuda, MD, MS, FAAN, FANA: Director, Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, UT Southwestern Medical Center; and
  • Deneen Vojta, MD: Executive Vice President, Global Research & Development, UnitedHealth Group.

“We are excited to bring together these patient entrepreneurs, judges and members of the Celgene and Lyfebulb teams for an engaging and interactive summit,” said Terrie Curran, President, Celgene Inflammation and Immunology. “Ultimately, we hope to foster discussion about ways to advance innovation in the space and look forward to awarding this grant that will help support people with MS and their families.”

About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, often debilitating disease that affects approximately 2.5 million people worldwide. In MS, an abnormal response of the body’s immune system causes inflammation and damage to myelin—the substance covering nerve fibers—in addition to damage to nerves themselves. Signs and symptoms are varied and can pose significant challenges in daily life.

About Lyfebulb
Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry (manufacturers and payers) to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, and depression/anxiety.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

For inquiries, please contact:

Lyfebulb
Karin Hehenberger, M.D., Ph.D., CEO
917-575-0210;

Winter and the BUGS

Autoimmune diseases such as MS, Rheumatoid arthritis, psoriasis, Crohn’s and ulcerative colitis all have the basic problem where the individual’s immune system turns against itself as opposed to fighting the outside world. Something beyond the genetic set up is needed to trigger the disease and so far, celiac disease (or gluten intolerance) is the only autoimmune disease where we know what the trigger is – gluten. There are about 100 different autoimmune diseases, and in the US alone, about 50M people suffer from one or more of these conditions.

Type 1 diabetes is also an autoimmune disease, but in contrast to the ones I mentioned above, the treatment is rather different due to the progression of the disease. When a person is diagnosed with T1D, their insulin-producing cells are almost already all gone. Although scientists have shown that the human pancreas may have some regenerative capacity under certain conditions (obesity and pregnancy for example), we are not leveraging that in today’s clinical practice since there is no drug approved for that purpose yet, and we have not come up with a safe way to combat the immune system at the same time. That is the very issue with T1D, it is a constant battle between the body’s own immune system which is trying to destroy insulin-producing cells, and the lack of the body’s regenerative capacity in the pancreas. This battle can be distorted for years, and that is why some people are diagnosed as toddlers while others in their 40s! When one is diagnosed as an older individual, most often the disease is less aggressive, and perhaps these individuals still have some cells left and thus some endogenous (their own) insulin capacity.

Back to the contrast with other autoimmune diseases – in diabetes the treatment is to replace the missing hormone, insulin or to enhance the effects of insulin, while in other autoimmune diseases the treatment is to reduce the autoimmune attack since the tissue that is being destroyed often is regenerated in between flares. For example, in Crohn’s disease, the intestine is the target, but during long periods of time, there are no symptoms at all, and the goal of course is to maintain that status for as much time as possible without impacting other functions of the immune system.

So what are the risks now that we are entering the winter months? Well, for one, the flu season is upon us, children are gathering inside rather than outside, incubating their germs and spreading them more easily. There is no good scientific episode to show that the cold weather would trigger virus and bacterial infections, but common sense still says we seem to get sicker when we are cold. A person with an autoimmune disease, who needs daily medication to inhibit the immune system from destroying an organ system or tissue, is more vulnerable to catching and developing a more serious infection. The bigger problem is when the individual has caught an infection, and it spreads, since the best way to limit the damage is to improve one’s own system, but by doing this, the autoimmune disease is less restricted and can cause a flare.

My personal situation is further complicated by two organ transplants and the medication I am taking to reduce the risk of rejecting those organs. When I develop an infection, my doctors often reduce the amount of immune suppressing medication I take to allow for my own system to get rid of the infection in addition to quickly determining what the agent is that we are dealing with so that the right kind of anti-infective medication can be put in place. Targeting the virus, bacteria or parasite correctly and quickly is of utmost importance, and today’s analytical equipment is quite sophisticated but it still often takes days for the final result. Prior to having that, the doctors often prescribe some super duper antibiotic to kill off a majority of bugs, and in my case, that lead to opportunistic bugs taking over last year and three bouts of clostridium difficile ensued. When the immune suppressants have been reduced, I face two major threats, one being rejecting my kidney and pancreas on the basis of foreign bodies inside my body, and the second one my own autoimmunity may flare up and start attacking the new pancreas, like it did my first one.

My advice to anyone with an autoimmune disease, or with an organ transplant, is to try to avoid getting sick! Easier said than done, and one cannot live one’s life inside a bubble, but there are a few simple precautions:

1: avoid interacting with large groups of people (especially young children) inside during the winter months

2: wash your hands after using public transportation and before having food or drinks

3: do not eat any raw foods in restaurants, including pre-cut fruits

4: ask for water without ice when traveling to exotic places

5: if someone at work or in school is sick, do not interact with them

6: as soon as you start feeling a cold coming on, take precautions such as hydrate, rest, and if you have a temperature, seek medical advice asap

7: make sure you have taken the flu shot and any other vaccinations appropriate in the locale you are residing

 

 

Diabetes and Tennis:When I Was First Diagnosed

I used to play tennis every day and often more than 1 hr each day – I loved the game and I was very good at it. This was before I was diagnosed with diabetes – after that, I never won again and I lost my love for the game completely.

I don’t think diabetes is 100% to blame for this, but probably at least 50 percent. When I was diagnosed, the summer of 1989, I had just reached the finals of a large national tournament in Sweden, and even though I lost in the final, I had done very well, especially since I had suffered from tonsillitis three times during the spring preceding this event, and I had been seriously injured the year before.

However, after my diagnosis I lost my confidence in my body. I had never had such a failure in my life and here I was, at 17 years of age (I spent my bday in the hospital getting trained on injections and glucose monitoring), feeling like I was suddenly disabled. Little did I know that the complications they warned me about during those first few weeks with diabetes would be a reality less than 20 years later and that I would go through two transplants before I turned 40!

Tennis represented so much to me as a young person, I spent most of my free time either playing tennis, getting to tournaments, working out to play better or preparing ahead of games. I loved going to my club and I even loved hanging out after tennis, relaxing and feeling the work-out in my body and if I had won, feeling strong and confident.

I guess the closest to this feeling in my current life, is when I present at conferences or when I have an important business meeting. I have the same feeling of anticipation, preparation and then during the presentation I have a high – triggered by endorphins and I am on top of the world for the duration of the event. The problem is coming down afterwards.  Being in the zone is all and well, but afterwards I feel empty, anxious and even sad.

As a diabetic, sometimes these events could be affected by my disease. For example, if my blood sugar was running low and I had to go up on the stage for a presentation, I would need to quickly eat something to avoid the risk of passing out and the absolute certainty of presenting poorly because my brain did not have enough sugar to work with. When I was high, I could also feel it, since I would get slower in my thoughts and especially in my reasoning. I would rather be high than low, and my solution to avoiding this roller coaster was to always keep myself slightly high, but not high enough to be slow, blurry-eyed or lethargic.

After getting my pancreas transplant in January of 2010 I have not experienced any of these feelings and it is such a relief and such an advantage! I sometimes say that I did not know how hard it was living with diabetes before I got a pancreas transplant and realized what normal life is supposed to be and how good I felt. Achieving that feeling for everyone with diabetes is our goal, and while we pursue the cure, we need to identify a range of products that can help people with daily life.

I hope that I will get back to tennis one day, but for some reason, tennis more than any other sport is linked to my life before diabetes that I lost. I know that I have a new chance, and should be incorporating tennis into my life, but it is easier for me to exercise otherwise without ever feeling that diabetes, transplants and age have had a negative effect on my performance!

Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology

Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology

 

  • Eleven finalists have been selected from a strong roster of talent to compete at the inaugural Lyfebulb-Helsinn  Innovation Summit, March 26-27, Monaco
  • The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer supportive care using drugs, medical devices, consumer products, or healthcare information technologies
  • The award will be presented to the finalist demonstrating outstanding science and entrepreneurial potential to bring their ideas to the market

Lyfebulb-Helsinn Innovation Award & Summit

MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, March 1, 2018:

 

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. The finalists are invited to compete at the Lyfebulb-Helsinn Innovation Summit & Award, which will be hosted on 26-27 March 2018, by Lyfebulb and Helsinn at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco.

Due to the high quality and quantity of applications this year, there will be 11 finalists:

  • Samuel Wagner of Batu Biologics, Inc
  • Massimo Bocchi of Cellply Srl
  • Walid Al-Akkad of Engitix Ltd
  • Gitte Pedersen of Genomic Expression, Inc
  • Lorenzo Pradella of GreenBone Ortho srl
  • Samir Housri of Mednet, Inc
  • Till Erdmann of Myelo Therapeutics GmbH
  • Christian Apfel of SageMedic, Inc
  • Aaron Horowitz of Sproutel, Inc
  • Thierry Desjardins of Surgisafe Ltd
  • Boaz Gaon of Wisdo Ltd

The Award will recognize outstanding potential among entrepreneurs who have demonstrated an ability to develop and bring to the market innovation designed to improve the quality of life of people with cancer using drugs, medical devices, consumer products and healthcare information technologies. The finalists represent companies of all sizes that have been founded by cancer patients, cancer survivors, or those with close relatives with cancer.

The finalists were selected by Karin Hehenberger, MD PhD, CEO and Founder of Lyfebulb, Leslie Brille, Chief Investment Officer, Lyfebulb, Riccardo Braglia, Helsinn Group Vice Chairman and CEO and Roberto De Ponti, Head of Corporate New Ventures and Strategic Investments, Helsinn International Services. The Innovation Summit has been founded upon Lyfebulb’s concept of Patient Entrepreneurship and Helsinn’s determination to provide the best supportive care for cancer patients and to improve the health and quality of life of every person affected by cancer. A “pitch session” will be held at the summit, where a winner will be selected from the eleven finalists by a panel of experts.

“At Lyfebulb, we interact with numerous individuals who are using their own experiences with chronic disease to originate and develop effective solutions to help others. The level of innovation demonstrated by people who submitted their ideas to the first Lyfebulb-Helsinn Innovation Award were of a very high caliber and we commend all of them. Core to Lyfebulb’s Mission is to empower individuals living with chronic disease, and by embracing patient entrepreneurs and furthering their ideas and businesses, we are doing exactly that.” says Dr. Karin Hehenberger.

Riccardo Braglia added, “I know from experience how a cancer diagnosis can often be a spur towards greater dynamism and entrepreneurship and have seen many examples of great innovation from people who have first-hand experience with the disease. I am looking forward to learning more about the potential of their concepts and am confident that the expertise and industry experience of the judging panel will help choose a finalist who can innovate to improve the lives of people with cancer.”

About Lyfebulb

Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and Inflammatory Bowel Disease.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About Helsinn International Services sarl

Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.  

About Helsinn Investment Fund S.A., SICAR

The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.

For more information, visit www.helsinninvestmentfund.com

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

For more information:

Helsinn Group Media Contact
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
For more information, please visit www.helsinn.com and follow us on TwitterLinkedIn and Vimeo.

Press Contact for Lyfebulb:

Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb,
Phone: + 00 1 917-575-0210
karin@lyfebulb.com
www.lyfebulb.com
We are on Twitter. Follow us @Lyfebulb

Inside the Patient Entrepreneur’s Mind with Sigurjón Lýðsson

Sigurjon Lydsson

Having a chronic-illness can be challenging, and running your own business can be hard. No matter where you fit on the spectrum, we could all use a little motivation.  Our #InsidethePatientEntrepreneursMind blog series gives you insight and life hacks on how to stay motivated from some of the most innovative patient entrepreneurs in the world.

Sigurjón Lýðsson is the CEO and Co-Founder of Medilync, a medical platform which builds cloud-based medical solutions where big data, IoT, and engagement are key to alleviating the burden of diabetes.

Sigurjón sat down with Lyfebulb to tell us how his father’s medical diagnosis with T1D, cancer and his short term memory lost motivated him to look for a solution that would help his family and medical provider manage the care of his father.

What motivated you to create a business addressing a disease you know so well?
My father has had Type I diabetes for apporx 40 years now. When growing up we usually didn’t notice that he had T1D, he never complained about it. Captain on a shipping vessel with 8-10 souls he was told he couldn’t do it. He never gave in. In later years he started to show symptoms of memory loss. We, his sons, would joke about that and so did he. But when he was diagnosed with cancer and it had spread to his brain, we got ever so more worried. At that time he had forgot if he’d measured his glucose or even if he injected or not. So when we were told his tumor would affect his memory I started looking for a solution for my dad. I could not find it! I still can’t as I am still trying to get it funded. I know I have the solution, but I fear it will be too late for my dad. If I can help anyone else live a better, safer life then I will be happy.

What are some of the hurdles you perceive exist for people with your disease?
Diabetes is one of the toughest disease out there. But information flow in general is what is the biggest hurdle today. Information from patients to clinicians is too cumbersome and usually only verbal from the patient to clinicians. We have a solution that has changed that.

Who are some of your role models in your space?
Not necessary in my field but Juan Mata Garcia is my latest role model. Kind person to those who need it, gives 1% of his Manchester United income to others. Bill Gates is another one I admire. Using his wealth to find a cure for polio for example, is just amazing.

What is your goal beyond creating a successful business?
Help people live better and safer lives.

What does Lyfebulb mean to you? How can we support you better? What are some of the biggest gaps today for a “young” entrepreneur?
Funding a company doing a hardware for diabetes is really difficult so anything in that area would definitely help.

How do you stay healthy and motivated to deliver?
As I am 75% likely, due to genes, to get Type II diabetes I do take care of my nutrition and I do cross-fit 5 times a week. That gives me the energy I need to get ahead of the curb.

How has mentorship made a difference in your professional and personal life?
Mentorships are key to new companies to a difficult market.

How can we draw more attention to user-driven innovation?
Solely by involving the users more.

How do you maintain work/life balance?
I would always be lying if I’d say that I can control it, but I do my best.

If you had three wishes, what would they be?
I could create a legacy which saves lives 2) My family be safe from harm 3) Peace on earth ☺.

What is your favorite song that gets you motivated?
My own song Unity 😉


#InsidethePatientEntrepreneursMind is a weekly blog series that highlights members of Lyfebulb’s Patient-Entrepreneur Circle. The Entrepreneur Circle is an educational and inspirational platform for all people living with, or affected by chronic disease. Existing entrepreneurs will be available to educate new dreamers through the website and through live events. To read more or to apply to join the Enrepreneur Circle click here.

A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award

The Award recognizes Patient Entrepreneurs’ Innovative Efforts and Ideas for cancer and cancer supportive care using drugs, medical devices, consumer products, or healthcare information technologies. Newly appointed jury panel members unveiled Deadline for submissions: January 22, 2018

MONACO, PRINCIPALITY OF MONACO and NEW YORK, NY, JANUARY, 9, 2018:Lyfebulb and Helsinn Investment Fund S.A., a fund focused on early-stage investments in areas of high unmet patient need, invite patient entrepreneurs that have embraced and endured the real life experiences of cancer to compete for the Lyfebulb-Helsinn Innovation Award. It has been announced today that:

  • Carolyn R. “Bo” Aldige, President and Founder of the Prevent Cancer Foundation
  • Stephen Squinto, PhD, Lyfebulb Chairman and Co-Founder, Venture Partner at Orbimed, and Co-Founder of Alexion
  • Professor Patrick Rampal, MD, President of the Scientific Center of Monaco
  • Professor Franco Cavalli, MD, Director of Oncology, Oncology Institute of Southern Switzerland
  • Professor Françoise Meunier, MD, EORTC Director Special Projects

are the newly-appointed jury panel members of the first Lyfebulb- Helsinn Innovation Award. The Award will recognize outstanding entrepreneurial potential to commercialize innovative efforts and ideas to better manage and improve the quality of life of cancer patients with respect, integrity, and quality, using drugs, medical devices, consumer products and healthcare information technologies. Established companies of all sizes founded by cancer patients, cancer survivors, or those having a close relative with cancer, who have created a product to address issues encountered by cancer patients, are invited to submit applications by January 22, 2018, through the Lyfebulb-Helsinn Innovation Summit & Award website, where more information regarding eligibility and key criteria can also be found.

Ten finalists will be selected by Karin Hehenberger, MD PhD, CEO and Founder of Lyfebulb, and Mr. Riccardo Braglia, Helsinn Group Vice Chairman and CEO, and invited to compete at the Innovation Summit which will be hosted on 26-27 March 2018, by Helsinn Investment Fund at the Monte-Carlo Bay Hotel and Resort, in Monaco, Principality of Monaco. The Summit is founded upon Lyfebulb’s concept of Patient Entrepreneurship and Helsinn’s determination to provide the best supportive care for cancer patients and to improve the health and quality of life of every person affected by cancer. At the summit, the top finalists will be chosen by a panel of experts through a special “pitch session.” In recognition of the best innovative efforts and ideas, a symbolic monetary prize of USD 25’000 will be given to the entrepreneur winner to advance his/her business and use his/her life expertise to help manage the burden of cancer.

“At Lyfebulb, we come into contact with many people who are putting their own experiences with cancer towards developing solutions to help others. Now, for the first time, patient entrepreneurs have the opportunity to receive exposure and financing toward their companies through a targeted event to help them advance their cause,” says Dr. Karin Hehenberger.

Riccardo Braglia added, “Lyfebulb is about encouraging the best in patient entrepreneurship, drawing on the talents of people with first-hand experience of the cancer journey to help develop innovative approaches to cancer supportive care, and this is very much aligned with Helsinn’s journey. We are delighted of the jury panel – their expertise, experience, industry knowledge and dynamism in helping people with cancer will be invaluable.”

About Lyfebulb
Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, Industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in Diabetes, the company has expanded disease states covered into Cancer and Inflammatory Bowel Disease.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Karin Hehenberger LinkedIn, and Lyfebulb LinkedIn.

About Helsinn Investment Fund
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients. Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.
For more information, visit www.helsinninvestmentfund.com

About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.

For more information:
Helsinn Group Media Contact
Paola Bonvicini
Group Head of Communication, Helsinn
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Info-hhc@helsinn.com
Please visit www.helsinn.com
We are on Twitter. Follow us @HelsinnGroup
We are on LinkedIn. Follow us @ Helsinn Group

Press Contact for Lyfebulb:
Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb,
Phone: + 00 1 917-575-0210
Email: karin@lyfebulb.com
Please visit www.lyfebulb.com
We are on Twitter. Follow us @Lyfebulb

Interests - Select all that apply